|
|
 |
| |
|
|
|
|
| |
Class |
|
| |
|
|
| |
|
A limited partnership managed under the
terms set forth by the Japanese Limited Partnership Act for Private
Equity Investment
|
|
|
|
General Partner |
|
|
|
|
|
|
Fast Track Initiative, Inc. |
|
|
|
Fund Size |
|
|
|
|
|
|
2.8 Billion Japanese Yen |
|
|
|
Major Limited partners |
|
|
|
|
|
|
Investment Company of Tokyo Metropolitan Government,
Development Bank of Japan, Shinkin Central Bank, Mizuho Securities,
etc. |
|
|
|
Term |
|
|
|
|
|
|
10 years (with 2 years extension allowed)
|
|
|
|
Investment target: Life Science and
Healthcare |
|
|
|
|
|
|
Life Sciences Area: New Drug Pipeline, New Screening
Methods, Cell Therapy, Regenerative Medicine, Diagnostic Methods,
Medical Equipments and Devices, Biotech Systems/Reagents, Informatics（Medical,
Genome, Proteome）, etc.
|
|
|
|
|
Healthcare Area: Clinical Trial Areas, Hospital Management
Support, Preventive Medicine Areas, Personal Health Areas, etc.
|
|
|
|
Investment Stage |
|
|
|
|
|
|
Seed and early stage
|
|
|
|
Expected # of investments |
|
|
|
|
|
|
10 to15 companies |
|
|
|
|
|
|
|
|
Fund
